Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H28F2O5 |
| Molecular Weight | 410.4515 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
InChI
InChIKey=WXURHACBFYSXBI-GQKYHHCASA-N
InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
| Molecular Formula | C22H28F2O5 |
| Molecular Weight | 410.4515 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00663Curator's Comment: Description was created based on several sources, including
Sources: http://www.drugbank.ca/drugs/DB00663
Curator's Comment: Description was created based on several sources, including
Flumethasone or flumetasone is a corticosteroid and is an agonist of a glucocorticoid receptor with anti-inflammatory, antipruritic and vasoconstrictive properties. Flumethasone is often formulated as the pivalic acid ester, flumetasone pivalate. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flumethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin. Flumethasone is used for the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin condition.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00663 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | LOCORTEN Approved UseThis medication is used in corticosteroid-responsive dermatoses. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30080272/ |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
FLUMETHASONE serum | Equus caballus population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.32 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30080272/ |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
FLUMETHASONE serum | Equus caballus population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30080272/ |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
FLUMETHASONE serum | Equus caballus population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Screening and quantitative confirmatory method for the analysis of glucocorticoids in bovine milk using liquid chromatography-tandem mass spectrometry. | 2010-12-15 |
|
| Quantitative determination of corticosteroids in bovine milk using mixed-mode polymeric strong cation exchange solid-phase extraction and liquid chromatography-tandem mass spectrometry. | 2010-12-01 |
|
| Quantification of corticosteroids in bovine urine using selective solid phase extraction and reversed-phase liquid chromatography/tandem mass spectrometry. | 2010-06-01 |
|
| Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010-04 |
|
| Simultaneous determination of corticosteroids, androgens, and progesterone in river water by liquid chromatography-tandem mass spectrometry. | 2010-02 |
|
| Pivotal Advance: Pharmacological manipulation of inflammation resolution during spontaneously resolving tissue neutrophilia in the zebrafish. | 2010-02 |
|
| Determination of anabolic steroids in muscle tissue by liquid chromatography-tandem mass spectrometry. | 2009-11-13 |
|
| Validation of a solid-phase extraction and ultra-performance liquid chromatographic tandem mass spectrometric method for the detection of 16 glucocorticoids in pig tissues. | 2009-06-03 |
|
| Development of a rapid method for the analysis of synthetic growth promoters in bovine muscle using liquid chromatography tandem mass spectrometry. | 2009-04-01 |
|
| A simple and rapid ESI-LC-MS/MS method for simultaneous screening of doping agents in urine samples. | 2009-04 |
|
| Lecithin based nanoemulsions: A comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behaviour and skin permeation. | 2009-03-31 |
|
| A liquid chromatography method using a monolithic column for the determination of corticoids in animal feed and animal feeding water. | 2008-08 |
|
| Optimization of solid phase extraction clean up and validation of quantitative determination of corticosteroids in urine by liquid chromatography-tandem mass spectrometry. | 2008-06-09 |
|
| Flexor carpi ulnaris tendonopathy in a Weimaraner. | 2007-10 |
|
| Rapid multi-residue method for the quantitative determination and confirmation of glucocorticosteroids in bovine milk using liquid chromatography-electrospray ionization-tandem mass spectrometry. | 2007-04-04 |
|
| Effect of selected fluorinated drugs in a "ringing" gel on rheological behaviour and skin permeation. | 2007-04 |
|
| High throughput HPLC-ESI-MS method for the quantitation of dexamethasone in blood plasma. | 2007-01-04 |
|
| A chromatography method for the screening and confirmatory detection of dexamethasone. | 2006-12 |
|
| Medical treatment of vulvar squamous cell hyperplasia. | 2006-12 |
|
| G-protein-coupled glucocorticoid receptors on the pituitary cell membrane. | 2005-08-01 |
|
| Regression of subcorneal pustular dermatosis type of IgA pemphigus lesions with azithromycin. | 2005-08 |
|
| Effect of steroidal and non-steroidal anti-inflammatory drugs on inflammatory markers in calves with experimentally-induced bronchopneumonia. | 2005-07-29 |
|
| Detection of synthetic corticosteroids in bovine urine by chemiluminescence high-performance liquid chromatography. | 2005-06-01 |
|
| Confirmation of synthetic glucocorticoids with liquid chromatography/mass spectrometry: organization and results of an international interlaboratory comparison test. | 2005-03-12 |
|
| Otic drops used to clear a blocked grommet: an in vitro prospective randomized controlled study with blinded assessment. | 2004-12 |
|
| Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. | 2004-09 |
|
| Development of a dual luciferase reporter screening assay for the detection of synthetic glucocorticoids in animal tissues. | 2003-12 |
|
| Effect of steroidal and non-steroidal anti-inflammatory drugs in combination with long-acting oxytetracycline on non-specific immunity of calves suffering from enzootic bronchopneumonia. | 2003-10-08 |
|
| Immunochemical screening and liquid chromatographic-tandem mass spectrometric confirmation of drug residues in edible tissues of calves injected with a therapeutic dose of the synthetic glucocorticoids dexamethasone and flumethasone. | 2003-01-01 |
|
| A high-performance liquid chromatography/tandem mass spectrometric screening method for eight synthetic corticosteroids in bovine feces and the simultaneous differentiation between dexamethasone and betamethasone. | 2002 |
|
| Determination of flumethasone in calf urine and serum by liquid chromatography-tandem mass spectrometry. | 2001-05-05 |
|
| Accelerated solvent extraction and liquid chromatography-tandem mass spectrometry quantitation of corticosteroid residues in bovine liver. | 2001-04-05 |
Patents
Sample Use Guides
Apply a sparingly thin layer of 0.02% cream, ointment or lotion over affected areas bid-tid for 7-10 days.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2379953
Flumethasone inhibited PAF-induced N-PMN (neutrophils from newborn calves) aggregation at the highest dose - 122 uM
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:33:05 GMT 2025
by
admin
on
Mon Mar 31 18:33:05 GMT 2025
|
| Record UNII |
LR3CD8SX89
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
D07BB01
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
WHO-VATC |
QD07CB05
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
WHO-VATC |
QD07BB01
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
WHO-VATC |
QD07XB01
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
CFR |
21 CFR 522.960A
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
CFR |
21 CFR 520.960
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
WHO-ATC |
D07AB03
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
WHO-VATC |
QS02CA02
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
WHO-ATC |
D07CB05
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
CFR |
21 CFR 522.960
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
CFR |
21 CFR 522.960C
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
WHO-ATC |
D07XB01
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
WHO-VATC |
QD07AB03
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
WHO-ATC |
S02CA02
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
CFR |
21 CFR 524.960
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
||
|
WHO-VATC |
QH02AB90
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
218-370-9
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
34764
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
4548
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
DTXSID2045365
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
54702
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
4458
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | RxNorm | ||
|
31623
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
100000080687
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
2135-17-3
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
LR3CD8SX89
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
FLUMETASONE
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
SUB07698MIG
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201392
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
m5439
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | Merck Index | ||
|
16490
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
LR3CD8SX89
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
DB00663
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
C65717
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
1355
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY | |||
|
D005443
Created by
admin on Mon Mar 31 18:33:05 GMT 2025 , Edited by admin on Mon Mar 31 18:33:05 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
DEGRADENT -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|